{"id":1877,"date":"2018-12-31T00:00:34","date_gmt":"2018-12-30T17:00:34","guid":{"rendered":"https:\/\/www.hivnat.org\/en\/?p=1877"},"modified":"2018-12-31T00:00:34","modified_gmt":"2018-12-30T17:00:34","slug":"management-using-the-latest-technologies-in-resource-limited-settings-to-optimize-combination-therapy-after-viral-failure","status":"publish","type":"post","link":"https:\/\/www.hivnat.org\/en\/studies\/1877\/","title":{"rendered":"Management Using the Latest Technologies In resource-limited settings to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE)"},"content":{"rendered":"\n\t\t\t\t\n<p><strong>Project no.:<\/strong> A5288 (NCT01641367)<\/p>\n\n\n\n<p>This is\na randomized, open labelled, multicentered international study that will assess\nthe efficacy, safety and tolerability of the combinations of new anti-HIV drugs\nwith and without anti-TB drug. This study will also assess whether text\nmessages can help improve adherence or not.<\/p>\n\n\n\n<p><strong>Results: <\/strong>From 2013-2015, 545 participants in 10 countries in Africa, Asia, South America and the Caribbean enrolled: 47% females; median age 41 years, median CD4 count 175 cells\/mm<sup>3<\/sup>. At enrollment, drug resistance (moderate or high-level) to 0, 1, 2, and 3 ARV classes was identified in 22%, 20%, 30% and 27% of participants, respectively. Overall, 64% (95% CI 60, 68%) had VL \u2264 200 copies\/ mL at week 48. Viral suppression and VF differed across cohorts. By week 48, Cohort A had the most Grade \u2265 3 adverse events (39%) and regimen discontinuations (13%). No differences in VL \u2264 200 copies\/mL at week 48 or VF \u2265 24 weeks were observed in the randomized comparison of B1 &amp; B2 cohorts.<\/p>\n\n\n\n<p>(Source: Grinsztejn\nB, et al., Results of ACTG A5288: A strategy study in RLS for 3<sup>rd<\/sup>-Line\nART candidates. Abstract #30LB. Presented at CROI 2018)<\/p>\n\t\t","protected":false},"excerpt":{"rendered":"<p>\t\t\t\tThis is a randomized, open labelled, multicentered international study that will assess the efficacy, safety and tolerability of the combinations of new anti-HIV drugs with and without anti-TB drug.\t\t<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-1877","post","type-post","status-publish","format-standard","hentry","category-studies"],"_links":{"self":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/1877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/comments?post=1877"}],"version-history":[{"count":0,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/1877\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/media?parent=1877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/categories?post=1877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/tags?post=1877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}